Silence Therapeutics Reports Increased Losses
Company Announcements

Silence Therapeutics Reports Increased Losses

Silence Therapeutics (SLN) has released an update.

Silence Therapeutics has reported a loss after taxation of £15,562,000 for the three months ended June 30, 2024, indicating a deeper loss compared to £10,401,000 for the same period in 2023. The company’s operating loss also increased to £18,323,000, up from £11,457,000 year-over-year. Despite the losses, the balance sheet shows a significant cash and cash equivalents increase to £109,482,000, up from £54,031,000 at the end of December 2023.

For further insights into SLN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlySilence Therapeutics files automatic ordinary shares offering
TheFlyAstraZeneca deal has positive read for Silence Therapeutics, says Morgan Stanley
TheFlyAstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App